Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
News Dec 10, 2013
Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec’s overall strategy of building up a pipeline of assets of which we have interest in future upside.”
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE